A Reliable Research Partner in Life Science and Medicine

## Recombinant Human PD-L1/B7-H1/CD274 Protein (Fc Tag)

Catalog Number: PKSH032872

Note: Centrifuge before opening to ensure complete recovery of vial contents.

$\mathbf{r}$		crip					
	00	0	РΤ	n	ŤΤ		m
v	$\mathbf{c}$	v.		w	w	w	ш

Species Human

**Source** HEK293 Cells-derived Human PD-L1;B7-H1;CD274 protein Phe19-Thr 239, with an C-

terminal Fc

Calculated MW52.4 kDaObserved MW70-80 kDaAccessionQ9NZQ7

**Bio-activity** Not validated for activity

#### **Properties**

**Purity** > 95 % as determined by reducing SDS-PAGE.

**Endotoxin** < 1.0 EU per µg of the protein as determined by the LAL method.

**Storage** Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80

°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of

reconstituted samples are stable at < -20°C for 3 months.

Shipping This product is provided as lyophilized powder which is shipped with ice packs.Formulation Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4.


Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants

before lyophilization.

Please refer to the specific buffer information in the printed manual.

**Reconstitution** Please refer to the printed manual for detailed information.

#### Data



> 95 % as determined by reducing SDS-PAGE.

#### Background

# Elabscience®

### Elabscience Biotechnology Co., Ltd.

A Reliable Research Partner in Life Science and Medicine

CD274; also known as B7-H1 or programmed death ligand 1 (PD-L1); is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. Programmed death-1 ligand-1 (PD-L1; CD274; B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. By binding to PD1 on activated T-cells and B-cells; PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly; it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.